Exelixis
EXEL
#1695
Rank
โ‚น840.29 B
Marketcap
โ‚น2,942
Share price
0.52%
Change (1 day)
68.72%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น23.93. In 2022 the company made an earnings per share (EPS) of โ‚น48.15 a decrease over its 2021 EPS that were of โ‚น62.52.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-51.83%
2022โ‚น48.15-22.97%
2021โ‚น62.52100%
2020โ‚น31.26-65.09%
2019โ‚น89.55-53.91%
2018โ‚น194.30333.96%
2017โ‚น44.77-260.61%
2016-โ‚น27.88-58.75%
2015-โ‚น67.58-42.45%
2014-โ‚น117.435.3%
2013-โ‚น111.5143.48%
2012-โ‚น77.72-264.29%
2011โ‚น47.31-165.88%
2010-โ‚น71.81-32.54%
2009-โ‚น106.44-17.65%
2008-โ‚น129.2575.86%
2007-โ‚น73.50-25.64%
2006-โ‚น98.848.33%
2005-โ‚น91.24-42.86%
2004-โ‚น159.6730.34%
2003-โ‚น122.50-5.23%
2002-โ‚น129.25-0.65%
2001-โ‚น130.10-51.88%
2000-โ‚น270.34

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
โ‚น295.74 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น268.67 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น153.90 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น335.39 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,195 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,190 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น157.13 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น844.80-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น70.96-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA